Literature DB >> 9631478

Tetrahydroaminoacridine, a cholinesterase inhibitor, and D-cycloserine, a partial NMDA receptor-associated glycine site agonist, enhances acquisition of spatial navigation.

P Riekkinen1, S Ikonen, M Riekkinen.   

Abstract

The present study examines the efficacy of single and combined treatments with an antiocholinesterase, tetrahydroaminoacridine (THA, i.p.), and a glycine-B site partial agonist, D-cycloserine (DCS, i.p.) to alleviate water maze (WM) spatial navigation defect induced by medial septal (MS) lesion. THA 3 and DCS at 3 or 10 mg/kg improved acquisition of the WM test, but only DCS improved spatial bias. These drugs had no effect on consolidation. A combination of THA 3 and DCS 10 mg/kg enhanced WM acquisition more effectively than either of the treatments on their own. This suggests that combined modulation of acetylcholine and NMDA mechanisms may have greater therapeutic effect to stimulate cognitive dysfunctions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9631478     DOI: 10.1097/00001756-199805110-00068

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  3 in total

1.  Flumazenil and tacrine increase the effectiveness of ondansetron on scopolamine-induced impairment of spatial learning in rats.

Authors:  M Diez-Ariza; C Redondo; M García-Alloza; B Lasheras; J Del Río; M J Ramírez
Journal:  Psychopharmacology (Berl)       Date:  2003-07-04       Impact factor: 4.530

2.  D-cycloserine enhances short-delay, but not long-delay, conditioned taste aversion learning in rats.

Authors:  Rachel A Davenport; Thomas A Houpt
Journal:  Pharmacol Biochem Behav       Date:  2008-10-07       Impact factor: 3.533

3.  D-cycloserine in prelimbic cortex reverses scopolamine-induced deficits in olfactory memory in rats.

Authors:  Marta Portero-Tresserra; Paula Cristóbal-Narváez; Margarita Martí-Nicolovius; Gemma Guillazo-Blanch; Anna Vale-Martínez
Journal:  PLoS One       Date:  2013-08-02       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.